Designated a JLab San Diego Alumni, Vivreon Biosciences is developing a new class of small molecule therapeutics for treatment of chronic diseases with a paticularemphasis on Alzheimers. The firm's candidate therapies defend healthy tissue by blocking an untapped inflammatory pathway.? The body's immune system -- cells, antibodies, and other proteins -- defend against foreign pathogens: viruses and bacteria. However, immune system can become overly aggressive and start to attack its own host, creating chronic autoimmune and inflammatory diseases. Calcium signaling plays a pivotal role in regulating this immune system activatio, with the entry of Calcium into immune cells required to initiate an inflammatory response. By blocking this calcium signaling, Vivreon is premised on the assumtpiuon that stopping unwanted inflammation can protect healthy tissues that might otherwise be damaged. Mis-regulated calcium signaling occurs in a number of diseases with high levels of inflamumation to include ulcerative colitis, Alzheimer's disease, and Parkinson's disease. Vivreon's technology targets this calcium signaling to slow chronic inflammation, minimize tissue damage and, in some cases, allow healthy tissue to restore itself.
